抗血管生成治疗是当今国际上抗肿瘤研究的热点之一。研究抗血管生成药物 ,必须建立有效实用的实验模型和评价标准 ,近年来在这方面有较多新的进展。本文介绍分子、细胞、器官组织和整体水平上目前常用以及新创建的抗血管生成药物筛选和研究的体内外模型 ,并分析了这些模型的特点。分子细胞水平等体外模型的优点是实验容易控制 ,操作较简单 ,实验费用较低 ,样品所需量较少。体内模型的优点是实验条件比较接近今后药物使用的环境。筛选的程序一般为先经体外筛选 ,再经器官组织水平的筛选和研究确证 ,然后应用肿瘤模型进行最终和全面的评价 Anti-angiogenesis therapy is one of the hot topics in anti-tumor research in the world today. To study anti-angiogenic drugs, we must establish an effective and practical experimental model and evaluation criteria. In recent years, there have been more new advances in this field. In this paper, we present in vitro and in vivo models of currently used and newly created anti-angiogenic drugs in vitro, in vivo, at molecular, cellular, organ and tissue levels, and analyze the characteristics of these models. The advantages of in vitro models such as molecular cellular level are that the experiment is easy to control, the operation is simpler, the experiment cost is lower, and the amount of sample required is less. The advantage of the in vivo model is that the experimental conditions are relatively close to the future use of the drug. Screening procedures are generally first by in vitro screening, and then by the level of organ tissue screening and research confirmed that, and then applied the tumor model for the final and comprehensive evaluation